Affiliation:
1. Department of Thyroid and Breast Surgery, the Nanchong City Central
Hospital Affiliated to North Sichuan Medical College, Nanchong,
China
Abstract
AbstractThe aim of the work was to systematically evaluate the efficacy and safety of
Vandetanib in the treatment of advanced medullary thyroid carcinoma (MTC). MeSH
entries to search for randomized controlled trials and clinical research
literature on the application of Vandetanib in the treatment of medullary
thyroid cancer from PubMed, Chinese national knowledge infrastructure (CNKI),
and Web of Science databases since their establishment until March 2023 were
used. In terms of efficacy, the analysis results showed that Vandetanib had a
significantly higher objective response rate compared to the control group using
placebo (OR=2.13, 95% CI: 1.38, 3.29). In terms of side effects,
Vandetanib significantly increases the incidence of hypertension, rash, and
diarrhea, and has statistical significance (p+<+0.05).
Vandetanib has a better therapeutic effect on MTC, but it also increases the
incidence of hypertension, rash, and diarrhea. Attention should be paid to the
relief of side effects when using it.